#USA #New York #Class Action #Gross Law Firm #Skye Bioscience

Skye Bioscience, Inc. Class Action Overview

The Gross Law Firm is reaching out to investors of Skye Bioscience, Inc. (NASDAQ: SKYE) regarding a pending class action lawsuit. The firm emphasizes the importance of acting promptly as the lead plaintiff deadline is set for January 16, 2026. This notice specifically addresses shareholders who purchased shares of SKYE within the established class period, which is from November 4, 2024, to October 3, 2025.

Why You Should Act Now

Investors who bought shares during this timeframe are encouraged to contact The Gross Law Firm for details about possible lead plaintiff appointments. Remember, being appointed as a lead plaintiff is not a requirement for participation in any recovery resulting from this lawsuit. The primary allegations outlined in the complaint suggest that the defendants made materially false or misleading statements concerning the effectiveness and prospects of the company's lead product candidate, nimacimab. This information, which had been presented to investors, purportedly exaggerated the clinical, regulatory, and commercial potential of nimacimab.

It's crucial for affected shareholders to register their information promptly via the provided links to ensure they receive continuous updates on the case's status.

Allegations Against Skye Bioscience

The allegations against Skye Bioscience center around three main points:
1. Ineffectiveness of Nimacimab: The complaint claims that Skye's leading product candidate, nimacimab, is less effective than previously disclosed.
2. Exaggerated Product Prospects: It further alleges that Skye overstated the clinical and commercial realities surrounding nimacimab.
3. Misleading Public Statements: As a result of these factors, the defendants' public communications were allegedly misleading at various points, impacting investor decision-making.

Given these serious claims, it’s vital for investors to understand their rights and options. The Gross Law Firm will assist shareholders in navigating the complexities of this class action. As part of the registration process, participants will benefit from a portfolio monitoring tool, designed to keep them informed about significant developments in their case.

Next Steps for Shareholders

Shareholders who qualify for this class action should take immediate action. To be part of potential recovery efforts, it's essential to register by the January 16, 2026, deadline. This process carries no financial obligations and ensures your voice is heard. Skepticism surrounding corporate entity practices makes it more important than ever for investors to secure their interests and rights in situations like these.

Through its steadfast commitment to investor advocacy, The Gross Law Firm aims to protect individuals from corporate misconduct. Their mission is underscored by a firm belief in accountability within the securities market, promoting responsible practices and transparency.

For additional information or to initiate your registration, visit The Gross Law Firm's website or directly contact their office at the following:

• - Phone: (646) 453-8903
• - Email: [email protected]

Conclusion

In conclusion, Skye Bioscience, Inc. shareholders must remain alert to the evolving legal landscape. The pending class action presents an opportunity for investors to seek redress for potential grievances they may have faced due to misleading corporate practices. The deadline is fast approaching, so prompt registration and engagement with The Gross Law Firm is highly advisable to safeguard your interests.